The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Data indicates that the therapy resulted in visual acuity gains and “achieved” non-inferiority to aflibercept at most time ...

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...